ShortedShorted

RADIOPHARM ORDINARY (RAD) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
just now

Radiopharm Theranostics (ASX:RAD) Progresses Pipeline with Multiple Clinical Milestones

Highlights Radiopharm Theranostics is advancing multiple clinical-stage therapeutic and diagnostic programs across oncology indications. Lead candidate RAD204 has completed two Phase I dose cohorts, with tumour uptake confirmed in all treated participants and recruitment underway for the third cohort. RAD202, RAD402 and RV01 continue progressing through Phase I studies. The diagnostic candidate RAD101 reported ~90% concordance with MRI in its Phase 2b study and is prog...

Continue reading
Kalkine
Neutral
just now

Radiopharm Theranostics (ASX:RAD): Why Are ASX Penny Stocks Facing a Catalyst Test?

Highlights Smaller ASX companies are being judged more closely on funding discipline and meaningful project milestones. Radiopharm Theranostics, Renascor Resources, Botanix Pharmaceuticals, Anson Resources and Dimerix highlight different parts of the sector. Cash runway, execution quality and catalyst delivery are becoming the key themes across the market. ASX penny stocks are facing a sharper c...

Continue reading
Kalkine
Neutral
just now

Radiopharm Theranostics (ASX:RAD) Announces Finance and Governance Leadership Changes

Highlights Radiopharm Theranostics will continue its service agreement with Acclime Australia for CFO, financial management, statutory reporting and company secretarial services. Aaron Laurita has been appointed CFO, succeeding Phillip Hains. Amritha Sushil has joined the company as Joint Company Secretary, effective immediately. Nathan Jong will continue serving as Joint Company Secretary alongside Sushil. Radiopharm Theranostics (ASX:RAD) has confirmed the continuation of its service agreem...

Continue reading
Kalkine
Neutral
just now

Radiopharm Theranostics Draws Attention After Insider Buying

Highlights Radiopharm Theranostics insiders continued accumulating shares despite recent market weakness. The healthcare-focused biotech company remains under close watch amid theranostics sector growth. Investor attention remains centred on insider confidence and clinical development progress. Radiopharm Theranostics continues attracting market attention as insider buying activity and growing interest in precision oncology shape sentiment around the emerging healthcare company. The Australia...

Continue reading
Kalkine
Neutral
just now

Why Is (ASX:RAD) Drawing Attention After Clinical Update?

Highlights Early clinical data signals encouraging tumour targeting Safety profile remains manageable across initial cohort Trial progresses toward higher dosing phase Radiopharm Theranostics has reported early-stage clinical progress, with initial findings pointing to targeted tumour uptake and a stable safety profile, supporting continued development of its investigational therapy. What Is Driving Momentum for (RAD)? Radiopharm Theranostics (ASX:RAD) has entered a significant phase in...

Continue reading
Kalkine
Neutral
just now

Radiopharm Theranostics (ASX:RAD) to Present Promising Early Data for HER2 Therapy at AACR 2026

Highlights Radiopharm Theranostics will present early clinical data from its HEAT trial at the American Association for Cancer Research Annual Meeting 2026. Initial results from three patients showed tumour uptake of 177Lu-RAD202 at the lowest 30 mCi dose. No dose-limiting toxicities or treatment discontinuations reported. The trial has been cleared to advance to a higher 130 mCi dose cohort following review by the Data Safety and Monitoring Committee. Radiopharm Theranostics Limited (ASX:RAD...

Continue reading
Kalkine
Neutral
just now

Radiopharm (ASX:RAD) Completes Phase 2b Dosing for Brain Metastases Imaging Trial

Highlights Radiopharm Theranostics has completed final patient dosing in the U.S. Phase 2b trial of 18F-RAD101. The study enrolled 30 patients with recurrent brain metastases from various solid tumors. The trial evaluates diagnostic accuracy against MRI with gadolinium. Interim results show 90% concordance with conventional imaging. Clinical trial readout is expected in June 2026. The company plans to transition to a Phase 3 pivotal trial. Radiopharm Theranostics (ASX:RAD) has reached a key m...

Continue reading
Kalkine
Neutral
just now

Radiopharm Theranostics (ASX:RAD) Advances RAD202 to Higher Dose Level in Phase 1 HEAT Trial

Highlights The DSMC has recommended advancing RAD202 to a 130mCi dose level in the Phase 1 HEAT trial. Radiopharm progresses from Cohort 2 to Cohort 3 in its HER2-positive solid tumour stud. Radiopharm expects to complete Phase 1 dose escalation by the end of 2026. RAD202 targets HER2, a well-established oncology biomarker in multiple solid tumours. Radiopharm Theranostics (ASX:RAD) has received a recommendation from the Data Safety and Monitoring Committee (DSMC) to proceed to the next dose ...

Continue reading
Kalkine
Neutral
just now

Radiopharm (ASX:RAD) Strengthens Clinical Pathway for RAD101 with Siemens Collaboration

Highlights Radiopharm Theranostics has signed a clinical supply agreement with Siemens Healthineers for RAD101 in the U.S. Interim Phase 2b data reported 90% concordance with MRI scans, meeting the primary endpoint. The agreement supports supply for an upcoming global Phase 3 registrational trial. RAD101 demonstrated tumour uptake and improved clarity over equivocal MRI findings. The program holds FDA Fast Track status for diagnosing recurrent brain metastases. Radiopharm Theranostics (ASX:RA...

Continue reading
Kalkine
Neutral
just now

Radiopharm Theranostics (ASX:RAD) Begins First-in-Human Trial of RAD 402 for Advanced Prostate Cancer

Highlights Radiopharm Theranostics has dosed the first patient in its Phase 1 RAD 402 trial for advanced prostate cancer. The therapy targets KLK3 and uses Terbium-161 to enable targeted radiopharmaceutical treatment. The trial will assess safety, tolerability, and early signs of clinical activity through dose escalation. Initial clinical data from the first two dose levels are expected in the second half of 2026. Radiopharm Theranostics (ASX:RAD) has begun clinical evaluation of RAD 402 with...

Continue reading
Kalkine
Positive
just now

Telix Pharma Gains Traction on Radiopharma Progress

Highlights Clinical updates strengthen pipeline outlook Radiopharma focus drives renewed market attention Financial position supports ongoing expansion Telix Pharmaceuticals is drawing attention as clinical progress and a focused radiopharmaceutical strategy support its long-term positioning in oncology innovation. Telix Advances Radiopharma Strategy Amid Market Focus Telix Pharmaceuticals Ltd (ASX:TLX) has recently attracted market attention as developments within its clinical pipeline...

Continue reading
Kalkine
Neutral
just now

Radiopharm Theranostics (ASX:RAD) Reports High MRI Concordance in Brain Metastases Imaging Trial

Highlights RAD101 achieved 90% concordance with MRI, meeting the primary endpoint in the Phase 2b trial. PET imaging showed selective uptake in brain metastases, improving detection over MRI alone. Early follow-up data indicates positive trends in sensitivity and specificity for RAD101. The study is on track for final data by June 2026, with FDA Fast Track status supporting development. Radiopharm Theranostics Limited (ASX:RAD) has released new interim findings from its Phase 2b clinical tria...

Continue reading
Kalkine
Neutral
just now

Radiopharm Theranostics (ASX:RAD) to Spotlight Oncology Pipeline at NWR Conference

Highlights Radiopharm Theranostics will participate in the NWR Virtual Healthcare Conference to showcase its oncology-focused innovations. CEO & Managing Director Riccardo Canevari will outline the company’s strategy and oncology pipeline. The company is advancing targeted radiopharmaceuticals for cancers with limited treatment options. Clinical-stage biopharmaceutical company Radiopharm Theranostics (ASX:RAD) (NASDAQ:RADX) has announced its participation in the upcoming NWR Virtual...

Continue reading
Kalkine
Neutral
just now

Radiopharm Theranostics (ASX:RAD) Advances Clinical Pipeline with Key Trial Progress and Funding Boost

Highlights Radiopharm Theranostics is advancing multiple radiopharmaceutical programs across clinical stages RAD 101 has reported 92% concordance with MRI in a Phase 2b brain metastases study RAD 202 and RAD 204 have progressed dose escalation studies with early tumour uptake observed BetaBart (RV-01) has entered clinical trials with the first patient dosed following FDA clearance The company has strengthened its funding position to support new patient dosing, regulatory milestones, and pipelin...

Continue reading